国际肿瘤学杂志最新文献

{"title":"Research progress on targeted treatment in ROS1-positive non-small cell lung cancer","authors":"Yao Jin, Y. Weng, Zexi Xu, M. Peng","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.008","url":null,"abstract":"ROS1 fusion gene is a new potential target for molecular targeted therapy of non-small cell lung cancer (NSCLC). In recent years, more and more scholars focus on ROS1 fusion gene. The results of in vitro experiments and clinical research both show that anaplastic lymphoma kinase (ALK) inhibitors have potent anti-tumor activity in ROS1-positive NSCLC patients, but drug resistance is still inevitable. At present, there is no standardized diagnosis and treatment path for ROS1-positive NSCLC. Therefore, further study on the ALK inhibitors of ROS1 is very important, which can provide a new therapeutic idea for targeted treatment and research of NSCLC patients. \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; Molecular targeted therapy; ROS1 fusion gene","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"17 1","pages":"745-749"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86037451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on the mechanism of β human papillomavirus induced cutaneous squamous cell carcinoma","authors":"Qingyu Ma, Junqin Liang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.011","url":null,"abstract":"Human papillomaviruse (HPV) infects squamous epithelium and induces hyperproliferative lesions. β human papillomavirus (β-HPV) is a common type of HPV according to the nucleic acid sequence of L1 protein. In recent years, the incidence of cutaneous squamous cell carcinoma (CSCC) has increased, β-HPV may be involved in the pathogenesis of CSCC. Besides, β-HPV inhibits p53 and pRb tumor suppressor genes through virus E6 and E7 proteins, which plays an important role in the initial stage of cancer. Therefore, the β-HPV is a target for preventing CSCC, especially for patients with immunosuppression who have received organ transplantation. \u0000 \u0000Key words: \u0000Neoplasms, squamous cell; Betapapillomavirus; Mechanism","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"32 1","pages":"760-763"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80062481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress of tumor vascular targeting drugs combined with PD-1/PD-L1 antibody in the treatment of digestive system tumors","authors":"王华庆 齐瑞丽, W. Ruili","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.009","url":null,"abstract":"In recent years, tumor vascular targeting drugs and programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors have made great progress in tumor therapy. However, monotherapy not only has limited efficacy, but also has drug resistance. The results of many clinical trials at home and abroad showed that the combination of the two were used in the treatment of different tumors of digestive system, such as esophageal cancer, gastric cancer and gastroesophageal junction cancer, liver cancer and so on, so the combination of vascular targeting drugs and PD-1/PD-L1 antibody may be a breakthrough program in tumor therapy because of their good efficacy and safety. \u0000 \u0000Key words: \u0000Molecular targeted therapy; Angiogenesis inhibitors; Digestive system neoplasms; PD-1; PD-L1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"20 1","pages":"750-754"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79283325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular signaling pathways and cancer pain in gastric cancer","authors":"Ziyang Xing, Chunxia Sun","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.010","url":null,"abstract":"The molecular signaling pathways in gastric cancer, such as mitogen-activated protein kinase, phosphoinoinositide 3-kinase/protein kinase B, AMP-activated protein kinase, cyclooxygenase 2/nuclear factor-κB and Wnt/β-catenin pathways are closely related to the occurrence and development of cancer pain. To understand the expression and role of gastric cancer molecular signaling pathway in cancer pain is expected to provide a new idea for the treatment of cancer pain. \u0000 \u0000Key words: \u0000Stomach neoplasms; Cancer pain; Signaling pathway","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"79 1","pages":"755-759"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84087580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in nonsurgical treatment of head and neck squamous cell carcinoma","authors":"Shoumei Zang, D. Yan, Sen-xiang Yan","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.007","url":null,"abstract":"Locally advanced head and neck squamous cell carcinoma requires a multidisciplinary approach, including surgery followed by radiotherapy, with or without chemotherapy, or definitive concurrent chemoradiotherapy. The application of induction chemotherapy remains controversial. Cetuximab has achieved satisfactory results in the treatment of head and neck squamous cell carcinoma. Immunocheckpoint inhibitors against the receptor programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have demonstrated clinical efficacy in head and neck squamous carcinoma. However, only a small subset of patients can benefit from anti-PD-1 and anti-PD-L1 monotherapy. To improve the effectiveness of immunotherapy, combined of immunotherapy and other treatments has become an alternative strategy. \u0000 \u0000Key words: \u0000Head and neck neoplasms; Radiotherapy; Cetuximab; Immunotherapy; Chemotherapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"70 1","pages":"741-744"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80374000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial energy metabolism mediated via HIF-1 involves the proliferation and apoptosis of renal clear cell carcinoma cells regulated by propofol","authors":"Zhen-guo Li, Yu-ming Zhang, Z. Zhen, Ru Zhang, Jing Zhu, Jun Wang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.002","url":null,"abstract":"Objective \u0000To investigate the role of mitochondrial energy metabolism mediated via hypoxia-inducible factor-1 (HIF-1) in the proliferation and apoptosis of renal clear cell carcinoma cells regulated by propofol. \u0000 \u0000 \u0000Methods \u0000We chose human renal clear cell carcinoma cell line RCC4 as the research object, which did not express VHL gene. The pcDNA3-VHL plasmid and the pcDNA3 empty plasmid were respectively transfected into RCC4 cells to obtain RCC4-VHL(+ ) cells stably expressing the exogenous VHL protein and RCC4-VHL(-) cells without expressing the VHL protein. These two kinds of cells were then exposed to propofol at dosage of 0, 25, 50 and 100 μmol/L. HIF-1 protein expression was detected by Western blotting in the two kinds of cells, cell proliferation activity and apoptosis rate were detected by flow cytometry, and mitochondrial energy metabolism was detected by energy metabolism analyzer. \u0000 \u0000 \u0000Results \u0000Compared with RCC4-VHL(-) cells, the relative expression of HIF-1α protein in RCC4-VHL(+ ) cells was significantly decreased (0.05±0.02 vs. 1.23±0.10, t=16.016, P<0.001). When propofol concentrations were 50 μmol/L and 100 μmol/L, the proliferation activity of RCC4-VHL(+ ) cells was significantly lower than that of RCC4-VHL(-) cells (50 μmol/L: 0.10±0.02 vs. 0.13±0.04, t=3.502, P=0.032; 100 μmol/L: 0.05±0.02 vs. 0.10±0.01, t=6.771, P=0.017), and the apoptotic rate was significantly higher than that of RCC4-VHL (-) cells [50 μmol/L: (35.50±1.84)% vs. (22.15±1.06)%, t=7.082, P=0.004; 100 μmol/L: (54.35±2.97)% vs. (35.10±3.25)%, t=10.241, P<0.001). Compared with 0 μmol/L propofol, 100 μmol/L propofol increased HIF-1α protein expression in RCC4-VHL (+ ) cells (0.93±0.05 vs. 0.04±0.02, t=18.500, P<0.001). Compared with RCC4-VHL(-) cells, the oxygen consumption rate (OCR) [(130.42±11.81) pmol/min vs. (48.27±7.66) pmol/min, t=11.672, P<0.001], basal aerobic respiration [(98.55±8.09) pmol/min vs. (41.63±6.21) pmol/min, t=11.162, P<0.001], aerobic maximum [(226.79±13.51) pmol/min vs. (70.18±6.82) pmol/min, t=20.697, P<0.001], non-mitochondrial respiration [(28.36±4.29) pmol/min vs. (8.92±1.70) pmol/min, t=8.426, P=0.001] and oxygen consumption rate of proton leak [(23.85±5.08) pmol/min vs. (7.80±1.24) pmol/min, t=6.139, P=0.006] were significantly increased in RCC4-VHL(+ ) cells, while the extracellular acidification rate (ECAR) was significantly decreased [(26.76±4.35) mpH/min vs. (39.48±5.17) mpH/min, t=3.765, P=0.010]. Compared with 0 μmol/L propofol added in RCC4-VHL(+ ) cells, 100 μmol/L propofol decreased OCR [(72.44±8.15) pmol/min vs. (131.56±9.04) pmol/min, t=9.751, P<0.001], basal aerobic respiration [(54.31±5.35) pmol/min vs. (96.49±6.86) pmol/min, t=9.697, P<0.001], aerobic maximum [(116.71±12.39) pmol/min vs. (219.53±11.80) pmol/min, t=12.019, P<0.001], non-mitochondrial respiration [(13.25±4.01) pmol/min vs. (29.04±5.11) pmol/min, t=4.862, P=0.002] and oxygen consumption rate of proton leak [(10.24±3.79) pmol/min vs. (22.92±4.12) pmol/min,","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"6 1","pages":"711-717"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74295276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FDG PET-CT在评估局部晚期非小细胞肺癌预后中的应用","authors":"冀胜军 付兆懿 张敏 路会玲, Ji Shengjun Fu Zhaoyi Zhang Min Lu Huiling","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.005","url":null,"abstract":"Objective \u0000To explore the value of 18F-FDG PET-CT in evaluating the prognosis of locally advanced non-small cell lung cancer (NSCLC) patients. \u0000 \u0000 \u0000Methods \u0000The clinical characteristics and 18F-FDG PET-CT parameters of 138 locally advanced NSCLC patients from 2013 to 2016 in Suzhou Municipal Hospital and People′s Hospital of Suzhou New District were analyzed retrospectively. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were measured. Area under the curve (AUC) of SUVmax, MTV and TLG were calculated to determine optimal cut-off value for patients grouping, with receiver-operating characteristic curve (ROC) analysis. Progression-free survival (PFS) and overall survival (OS) were assessed by Kaplan-Meier method and the survival difference between the two groups was estimated by log-rank test. Multivariate survival analysis was performed by Cox proportional hazard model. \u0000 \u0000 \u0000Results \u0000According to ROC analysis, SUVmax (AUC=0.716, cut-off value was 11.8, P<0.001) had a better predictive value for OS, whereas the predictive values of MTV (AUC=0.580, P=0.101) and TLG (AUC=0.635, P=0.005) were less. There was no significant correlation between SUVmax and patients′ age (χ2=1.222, P=0.269), gender (χ2=0.029, P=0.865), TNM stage (χ2=0.073, P=0.787), pathologic subtype (χ2=0.541, P=0.462), smoking (χ2=0.266, P=0.606), differentiation (χ2=0.285, P=0.593) or tumor location (χ2=0.509, P=0.476). The 1-year, 2-year and 3-year OS rates of low SUVmax group (n=59) were 93.2%, 67.0% and 15.6% respectively, and those of high SUVmax group (n=79) were 77.2%, 25.0% and 5.62% respectively. The OS rate of low SUVmax group was higher than that of high SUVmax group (χ2=19.153, P<0.001). The 1-year and 2-year PFS rates of low SUVmax group were 79.3% and 56.9% respectively, and those of high SUVmax group were 46.2%, 13.0% respectively. The PFS rate of low SUVmax group was higher than that of high SUVmax group (χ2=25.945, P<0.001). Single factor analysis showed that differentiation (HR=1.839, 95%CI: 1.161-2.913, P=0.017), SUVmax (HR=0.357, 95%CI: 0.231-0.550, P<0.001), MTV (HR=0.470, 95%CI: 0.270-0.819, P=0.001) and TLG (HR= 0.508, 95%CI: 0.327-0.789, P=0.002) were independent influencing factors of OS. The degree of differentiation (HR=1.909, 95%CI: 1.167-3.123, P=0.018) and SUVmax (HR=0.250, 95%CI: 0.160-0.410, P<0.001) were the independent influencing factors of PFS. Multivariate analysis showed that only SUVmax was an independent influencing factor of OS (HR=2.189, 95%CI: 1.222-3.189, P=0.008)and PFS (HR=4.412, 95%CI: 2.318-8.398, P<0.001). \u0000 \u0000 \u0000Conclusion \u0000PET-CT SUVmax of primary tumor is significantly correlated with OS and PFS of patients. It has important guiding value for prognosis judgment and treatment plan selection of patients with locally advanced NSCLC. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; 18F-FDG PET-CT; Prognosis","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"65 1","pages":"728-733"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81490944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress of prognostic evaluation in thymoma","authors":"Ruiyun Zhang, Hui Luo, Y. Duan, H. Ge","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.012","url":null,"abstract":"Thymoma is the most common primary malignant tumor which occurs in the anterior mediastinum. The incidence of thymoma is relatively low with scarce large sample and multicenter studies available on the prognostic factors of these patients, and the related indexes for evaluating the prognosis are still under investigation. Looking for possible predictive indicators for prognosis evaluation, we can grasp the initiative of diagnosis, seize the opportunity of treatment, and intervene in the poor prognostic factors, thereby improving the prognosis of patients. \u0000 \u0000Key words: \u0000Thymoma; Prognosis; Thymic epithelial tumors","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"13 1","pages":"764-768"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91250317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy of S-1 combined with gefitinib in the treatment of advanced NSCLC with EGFR-TKI acquired drug resistance","authors":"Jing-yan Shen, B. Han, Shuying Wang, Hai-Li Kang, Lidong Wang, Xu-hui Liu, Qinggui Cui","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.004","url":null,"abstract":"Objective \u0000To explore the clinical effect of S-1 combined with gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). \u0000 \u0000 \u0000Methods \u0000A total of 74 patients with advanced NSCLC were selected as the study subjects from January 2016 to August 2017 in Qian′an People′s Hospital of Hebei Province. The patients were divided into control group (n=37) and experimental group (n=37) by random number table method. The control group was given sequential gefitinib with pemetrexed, and the experimental group was given S-1 combined with gefitinib. The clinical efficacy and adverse reactions of the two groups were compared. \u0000 \u0000 \u0000Results \u0000The effective rates of the control group and the experimental group were 21.62% (8/37) and 27.03% (10/37) respectively, and the difference was not statistically significant (χ2=0.294, P=0.588). The disease control rates were 75.68% (28/37) and 78.38% (29/37) respectively, and the difference was not statistically significant (χ2=0.076, P=0.782). The median progression-free survival of the control group and the experimental group were 8.4 months and 8.2 months, and the median overall survival were 9.8 months and 10.5 months respectively, and the differences were not statistically significant (χ2=0.186, P=0.666; χ2=0.608, P=0.436). The occurrence rate of diarrhea was 56.76% (21/37) in the control group and 62.16% (23/37) in the experimental group, with no significant difference (χ2=0.224, P=0.636). The occurrence rates of rash in the control group and the experimental group were 62.16% (23/37) and 13.51% (5/37), the occurrence rates of leukopenia were 35.14% (13/37) and 5.41% (2/37), the occurrence rates of thrombocytopenia were 27.03% (10/37) and 2.70% (1/37), the occurrence rates of anemia were 40.54% (15/37) and 10.81% (4/37), and the occurrence rates of liver damage were 18.92% (7/37) and 0 (0/37). The occurrence rates of the above adverse reactions in the experimental group were significantly lower than those in the control group, and the differences were statistically significant (χ2=18.615, P<0.001; χ2=10.118, P=0.001; χ2=8.650, P=0.003; χ2=8.568, P=0.003; χ2=5.680, P=0.017). There were no grade Ⅲ-Ⅳ adverse reactions in the two groups. \u0000 \u0000 \u0000Conclusion \u0000The combination of S-1 and gefitinib is effective in the treatment of advanced NSCLC with acquired resistance to EGFR-TKI and well tolerated, with mild adverse reactions, and oral administration is easy for patients to accept. It is an ideal way for clinical treatment of advanced NSCLC with EGFR-TKI acquired resistance. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; Pemetrexed; Epidermal growth factor receptor-tyrosine kinase inhibitor; Acquired drug resistance; S-1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"3 1","pages":"723-727"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82883118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of serum low density lipoprotein for first-line treatment in extensive-stage small cell lung cancer","authors":"Meng Tian, Zhenxiang Li, C. Fu, Baosheng Li, Xinchen Sun","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.006","url":null,"abstract":"Objective \u0000To investigate the relationship between serum low density lipoprotein (LDL) and the progression-free survival (PFS) of small cell lung cancer (SCLC) patients. \u0000 \u0000 \u0000Methods \u0000A total of 271 SCLC patients admitted to Shandong Cancer Hospital from May 1, 2014 to October 31, 2018 were selected. These patients were divided into limited-stage group (n=126) and extensive-stage group (n=145) according to Veteran′s Administration Lung Cancer Study Group (VALSG) evaluation standard. The correlation between the level of serum LDL before treatment and PFS was analyzed by Spearmen test in the two groups. After finding the cutoff value of LDL level by receiver operating characteristic curve (ROC) analysis, the relationship between LDL level before treatment and PFS was analyzed. According to the dynamic change of serum LDL during the treatment, extensive-stage patients were divided into four groups: normalized LDL group (n=25, patients whose LDL≤2.55 mmol/L and never increased until progression), increased LDL group (n=31, patients whose LDL≤2.55 mmol/L and increased at least once until progression), never-normalized LDL group (n=33, patients whose LDL>2.55 mmol/L and never normalized until progression), and decreased LDL group (n=56, patients whose LDL>2.55 mmol/L and decreased at least once until progression). Then the PFS among the four groups was compared. The survival curves were plotted by the Kaplan-Meier method and compared using the log-rank test. The significance of the independent variables for PFS in extensive-stage patients was analyzed using the Cox proportional hazards model. \u0000 \u0000 \u0000Results \u0000The median PFS for the whole cohorts was 7.1 months (1.4-27.1 months). The median PFS for limited-stage patients and extensive-stage ones was 8.8 months and 6.1 months respectively, with a significant statistical difference (χ2=28.723, P 2.55 mmol/L, n=164) for whole cohorts (9.0 months vs. 6.2 months, χ2=16.064, P 2.55 mmol/L before treatment (HR=0.436, 95%CI: 0.297-0.640, P 2.55 mmol/L and never normalized until progression (HR=2.215, 95%CI: 1.403-3.497, P 2.55 mmol/L before treatment (HR=0.435, 95%CI: 0.300-0.632, P 2.55 mmol/L and never normalized until progression (HR=2.028, 95% CI: 1.386-2.966, P<0.001) were independent risk factors for PFS, LDL normal during treatment (HR=0.318, 95%CI: 0.186-0.542, P<0.001) was independent protective factors of PFS. \u0000 \u0000 \u0000Conclusion \u0000The serum LDL level may be used as a potential predictive marker for PFS in extensive-stage SCLC patients subjected to the first-line chemotherapy. \u0000 \u0000 \u0000Key words: \u0000Lipoproteins, LDL; Small cell lung carcinoma; Treatment outcome; Forecasting; Progression-free survival","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"83 1","pages":"734-740"},"PeriodicalIF":0.0,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83779511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}